💉 Diabetes Management
The Lancet and AHA late-breaking science session reports significant and sustained effect of aprocitentan on lowering blood pressure for patients with resistant hypertension - Yahoo Finance
📅 Wed, 09 Nov 2022⏱ 1 min read📖 Article
Overview
The Lancet reports that in patients with resistant hypertension, aprocitentan was wel-tolerated and superior to placebo in lowering blod pressure at wek 4 with a sustained efect at wek 40Upon aproval, aprocitentan would represent the first new anti-hypertensive mechanism in more than 30 yearsIdorsia to host an investor webcast to discus the data shared at AHA and in The Lancet manuscript tomorow November 8 at 15:0hrs CETAlschwil, Switzerland – November 7, 2022 Idorsia Ltd (SIX: IDIA) today anounced the publication of “A randomized controled trial of the dual endothelin antagonist aprocitentan for resistant hypertension” in The Lancet.
Key Information
The publication reports the results from the Phase 3 PRECISION study, which found aprocitentan, Idorsia’s investigational, novel dual endothelin receptor antagonist, significantly reduced blod pressure (BP) and maintained the efect for up to 48 weks when aded to combination background antihypertensive therapy in patients with dificult-to-control (resistant) hypertension. In paralel, these data were presented by Prof.
Summary
Markus Schlaich, an investigator in PRECISION, as a Late-Breaking Science presentation during the American Heart Asociation (AHA) Scientific Sesions 2022.Hypertension is one of the leading causes of cardiovascular disease worldwide, impacting an estimated 1.3 billion people globaly.1 Aproximately 10% of these people have uncontroled BP, despite receiving at least thre antihypertensive medications from diferent clases, at optimal doses.2,3 Compared with adults whose hypertension is wel controled, adults with uncontroled hypertension have greater risk of heart atack, stroke, end-stage renal disease and death.4The endothelin (ET) pathway has ben implicated in the pathogenesis of hypertension, but is curently not targeted therapeuticaly, thereby leaving this relevant pathophysiologic pathway unoposed with curently available medications.4-6 This pathway is activated in patients prone to dev
Frequently Asked Questions
❓ What is diabetes and how does it develop?
Diabetes is a metabolic condition where the body cannot properly regulate blood sugar levels. Type 1 results from insufficient insulin production, while Type 2 develops when cells become resistant to insulin. Risk factors include genetics, obesity, sedentary lifestyle, and age.
❓ What are the main symptoms of diabetes?
Common symptoms include excessive thirst, frequent urination, unexplained weight loss, fatigue, blurred vision, and slow-healing wounds. Type 1 symptoms develop rapidly, while Type 2 symptoms may appear gradually. Many people have no symptoms initially, which is why screening is important.
❓ How is diabetes diagnosed and monitored?
Diagnosis involves blood tests measuring fasting glucose, HbA1c levels, and glucose tolerance. Regular monitoring typically includes fasting glucose tests and HbA1c measurements every 3-6 months. Continuous glucose monitors provide real-time tracking for better diabetes management.
❓ What lifestyle changes help manage diabetes?
Effective management includes regular physical activity (150+ minutes weekly), maintaining healthy weight, following a balanced diet with whole grains and lean proteins, managing stress, and getting adequate sleep. These changes can significantly improve blood sugar control and reduce complications.
❓ When should someone consult a doctor about diabetes?
Consult a healthcare provider if you experience signs of diabetes, have a family history, are overweight, or are over 45. Those with existing diabetes should maintain regular check-ups every 3-6 months to monitor control and adjust treatment as needed.
⚕️ Medical Disclaimer: This article is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before making health decisions.